Thomas Leggett, the Chief Financial Officer of Stoke Therapeutics, Inc. (NASDAQ: STOK), disposed of 5,378 shares of common stock across multiple trades on March 17 and March 18, 2026, according to the Form 4 filing with the Securities and Exchange Commission.
The aggregate proceeds from those transactions totaled $147,144. Trade execution prices spanned from $31.28 to $33.38 per share.
Transaction details filed with the SEC specify the following breakdown:
- On March 17, Leggett sold 1,274 shares at a weighted average price of $32.7394, with individual sale prices ranging from $31.995 to $32.99.
- Also on March 17, he sold 922 shares at a weighted average price of $33.3754, with prices ranging from $33.00 to $33.855.
- On March 18, Leggett sold 2,173 shares at a weighted average price of $31.2838, with prices ranging from $30.59 to $31.58.
- Additionally on March 18, he sold 172 shares at a weighted average price of $31.7888, with prices ranging from $31.60 to $32.46, and 37 shares at $32.85.
The filing characterizes the sale as an issuer-mandated transaction to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units. After these dispositions, Leggett is reported to directly hold 10,172 shares of Stoke Therapeutics common stock.
Market performance surrounding the trades has been volatile. The stock declined 9% over the most recent week even as it has appreciated 302% over the past year. Separately, InvestingPro analysis is cited as indicating that STOK appears slightly overvalued relative to its Fair Value at current levels, and that Pro Research Reports covering STOK and a broad universe of US equities are available for investors seeking more detailed research.
Several other corporate and market developments were disclosed recently that bear on the company’s outlook. Stoke Therapeutics’ Board of Directors approved a discretionary bonus of $697,125 for CEO Ian F. Smith, explicitly recognizing contributions tied to the company’s clinical and financial performance since his appointment.
On the analyst front, Guggenheim has initiated coverage of Stoke Therapeutics with a Buy rating, citing optimism about the company’s lead asset, zorevunersen, which is being developed as a treatment for Dravet syndrome. Cantor Fitzgerald has maintained its Overweight rating as regulatory discussions with the U.S. Food and Drug Administration proceed around potential expedited pathways for zorevunersen.
At the same time, the company disclosed a delay in the Phase 3 EMPEROR study timeline for zorevunersen. Enrollment completion is now expected in the second quarter of 2026, with a data readout anticipated in mid-2027. Stoke Therapeutics plans to begin a rolling New Drug Application submission to the FDA in the first half of 2027.
These items together underscore the mixed signal environment around Stoke Therapeutics: routine insider tax-related selling, significant near- and longer-term clinical milestones for the lead program, active analyst attention, and corporate compensation actions. Investors evaluating STOK will need to weigh the timing of clinical readouts and regulatory interactions alongside current valuation metrics and recent share-price volatility.